Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
By V. Gopalakrishnan, C. Spencer, L. Nezi, A. Reuben, M. Andrews, T. Karpinets, P. Prieto, D. Vicente, K. Hoffman, S. Wei and 60 more. Science, 2017
4,226 citations recorded by the source corpus.
Good bacteria help fight cancer Resident gut bacteria can affect patient responses to cancer immunotherapy (see the Perspective by Jobin). Routy et al. show that antibiotic consumption is associated with poor response to immunotherapeutic PD-1 blockade. They profiled samples from patients with lung and kidney cancers and found that nonresponding patients had low levels of the bacterium Akkermansia muciniphila. Oral supplementation of the bacteria to antibiotic-treated mice restored the response to immunotherapy. Matson et al. and Gopalakrishnan et al. studied melanoma patients receiving PD-1 blockade and found a greater abundance of “good” bacteria in the guts of responding patients. Nonresponders had an imbalance in gut flora composition, which correlated with impaired immune cell activity. Thus, maintaining healthy gut flora could help patients combat cancer. Science, this issue p. 91, p. 104, p. 97; see also p. 32 Gut bacteria influence patient response to cancer therapy. Preclinical mouse models suggest that the gut microbiome modulates tumor response to checkpoint blockade immunotherapy; however, this has not been well-characterized in human cancer patients. Here we examined the oral and gut microbiome of melanoma patients undergoing anti–programmed cell death 1 protein (PD-1) immunotherapy (n = 112). Significant differences were observed in the diversity and composition of the patient gut microbiome of responders versus nonresponders. Analysis of patient fecal microbiome samples (n = 43, 30 responders, 13 nonresponders) showed significantly higher alpha diversity (P < 0.01) and relative abundance of bacteria of the Ruminococcaceae family (P < 0.01) in responding patients. Metagenomic studies revealed functional differences in gut bacteria in responders, including enrichment of anabolic pathways. Immune profiling suggested enhanced systemic and antitumor immunity in responding patients with a favorable gut microbiome as well as in germ-free mice receiving fecal transplants from responding patients. Together, these data have important implications for the treatment of melanoma patients with immune checkpoint inhibitors.
Subfields: Dermatology, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/9974af509fc6a420b2e11c14e602fcf26cea86ee
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Dermatology
In Molecular Biology
- Curtis Huttenhower
- Nicola Segata
- Eric A. Franzosa
- F. Asnicar
- George Weingart
- Rob Knight
- S. Lynch
- J. Petrosino
In Oncology
Citations in the corpus
- Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018, background): “muciniphila, Ruminococcaceae, and Faecalibacterium to a favorable outcome to anti-PD-1 treatment (98, 126) Together, these findings suggest that human patients too may benefit from appropriate management of their intestinal flora while undergoing immune checkpoint inhibitor treatment.”
- Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3 (2020, background): “…mechanisms of multi-organism biochemical responses in the environment (Alivisatos et al., 2015; Blaser et al., 2016) , or the epidemiology of the human microbiome for biomarkers and therapy (Gopalakrishnan et al., 2018; Le Chatelier et al., 2013; Thomas et al., 2019; Zeller et al., 2014) .”
- Targeting FTO suppresses cancer stem cell maintenance and immune evasion (2020, positive): “Monoclonal antibodies targeting the PD-1/PD-L1/PD-L2 axis have achieved encouraging effects in clinical practice in treating multiple types of solid tumors (Gopalakrishnan et al., 2018; Patnaik et al., 2015; Topalian et al., 2012), but demonstrated only limited effects in AML (Berger et al.”
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic (2018, background): “inflamed gene expression profile (GEP) [26], immune gene expression signatures [27, 28], as well as description of the microbiome [29-31] also represent emerging predictive”